Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The US FDA has issued a letter to veterinarians clarifying the agency's stance on the use of tylosin phosphate in beef cattle.
In 2018, the stand-out M&A deals targeted diagnostics, digital technologies and nutrition. While Zoetis and Merck Animal Health made multi-billion-dollar deals, some of the sector's smaller purchases also hinted towards important trends. Animal Pharm editor Joseph Harvey looks back at where the money was spent.
The US FDA is working with Pfizer to alleviate a shortage of specific injectable opioids to treat pain in animals.
The US FDA has reported a 33% year-on-year drop in domestic sales and distribution of medically important antimicrobials for use in food-producing animals in 2017.
Stonehaven Incubate has partnered with antimicrobial protein specialist Lysando to develop therapies for companion animal infections.
McDonald's has kept a promise it made earlier this year by adopting a policy to reduce the use of medically important antibiotics across 85% of its global beef supply chain.
Sirona Biochem has commenced a proof-of-concept study for its SGLT2 inhibitor as a potential diabetes treatment for cats.
ImmuCell has been issued USDA approval for Dual-Force First Defense.
Bayer Animal Health is working with US biopharmaceutical firm ParaTheraTech (PTT) to develop a cryptosporidiosis treatment for food-producing animals.
Pet oncology specialist AdvaVet is targeting an initial public offering (IPO) on the Nasdaq Capital Markets next year.
European authorities have given the green light for the approval of Virbac's Kriptazen (halofuginone).
The US FDA's Center for Veterinary Medicine has approved Boehringer Ingelheim Vetmedica's Pexion (imepitoin tablets) to treat noise aversion in dogs.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.